Automated Flow Cytometry Assay Facilitates Monitoring of T Cell Health for Cell Therapy Manufacturing
Description: T cells are the therapeutic backbone of many cell therapies, and their functional quality impacts manufacturing success, product quality, and potency. Cell viability is a common critical quality attribute, but viability status alone provides limited insight into cell health. Early apoptosis in T cells can compromise multiple steps in the manufacturing workflow before the loss of membrane integrity is detected. Assessing T cell health by distinguishing non-apoptotic/viable, early apoptotic, and late apoptotic/dead cells provides a more informative metric for quality control. We are developing an Accellix T Cell Health Assay (Non-Lyse), combining canonical T cell phenotyping (CD45, CD3, CD4, and CD8) with Annexin V and viability dye, for rapid measurement of T cell health states (viable, apoptotic, late apoptotic/dead) in samples critical for cell therapy development and manufacturing, reducing operator-dependent error and subjective analysis.
Provide the following information and we’ll email you a copy of the poster:
*Required field
